1. Home
  2. Pharma & Healthcare
  3. Global Castrate Resistant Prostate Cancer Therapeutics Supply, Demand and Key Producers, 2023-2029

Global Castrate Resistant Prostate Cancer Therapeutics Supply, Demand and Key Producers, 2023-2029

Publication Month: Feb 2023 | No. of Pages: 112 Published By: Global Info Research
Single User License: US $ 4480
Corporate User License: US $ 8960

Prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels. Many early-stage prostate cancers need normal levels of testosterone to grow, but castrate-resistant prostate cancers do not. Also called CRPC.
The treatment of castration-resistant prostate cancer is to use various methods to treat the recurrence and metastasis of cancer cells or to control hormones.
This report studies the global Castrate Resistant Prostate Cancer Therapeutics demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Castrate Resistant Prostate Cancer Therapeutics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Castrate Resistant Prostate Cancer Therapeutics that contribute to its increasing demand across many markets.
The global Castrate Resistant Prostate Cancer Therapeutics market size is expected to reach $ 31890 million by 2029, rising at a market growth of 10.7% CAGR during the forecast period (2023-2029).
Global key players of castrate resistant prostate cancer therapeutics include Pfizer, Johnson & Johnson, AstraZeneca, Bayer, Jiangsu Hengrui Pharmaceuticals etc. The top five players hold a share over 70%. North America is the largest market, has a share over 40%, followed by Europe, and Asia-Pacific, with share 28% and 22%, separately.
Highlights and key features of the study
Global Castrate Resistant Prostate Cancer Therapeutics total market, 2018-2029, (USD Million)
Global Castrate Resistant Prostate Cancer Therapeutics total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Castrate Resistant Prostate Cancer Therapeutics total market, key domestic companies and share, (USD Million)
Global Castrate Resistant Prostate Cancer Therapeutics revenue by player and market share 2018-2023, (USD Million)
Global Castrate Resistant Prostate Cancer Therapeutics total market by Type, CAGR, 2018-2029, (USD Million)
Global Castrate Resistant Prostate Cancer Therapeutics total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Castrate Resistant Prostate Cancer Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer/Astellas (Xtandi), Johnson & Johnson, AstraZeneca/Merck (Lynparza), Bayer, Jiangsu Hengrui Pharmaceuticals, CTTQ, Sanofi, Hansoh and Clovis Oncology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Castrate Resistant Prostate Cancer Therapeutics market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Castrate Resistant Prostate Cancer Therapeutics Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Castrate Resistant Prostate Cancer Therapeutics Market, Segmentation by Type
Hormonal Therapy
Chemotherapy
Others
Global Castrate Resistant Prostate Cancer Therapeutics Market, Segmentation by Application
Hospital
Specialty Clinic
Others
Companies Profiled:
Pfizer/Astellas (Xtandi)
Johnson & Johnson
AstraZeneca/Merck (Lynparza)
Bayer
Jiangsu Hengrui Pharmaceuticals
CTTQ
Sanofi
Hansoh
Clovis Oncology
Zhendong Pharmaceutical
Key Questions Answered
1. How big is the global Castrate Resistant Prostate Cancer Therapeutics market?
2. What is the demand of the global Castrate Resistant Prostate Cancer Therapeutics market?
3. What is the year over year growth of the global Castrate Resistant Prostate Cancer Therapeutics market?
4. What is the total value of the global Castrate Resistant Prostate Cancer Therapeutics market?
5. Who are the major players in the global Castrate Resistant Prostate Cancer Therapeutics market?
6. What are the growth factors driving the market demand?

1 Supply Summary
1.1 Castrate Resistant Prostate Cancer Therapeutics Introduction
1.2 World Castrate Resistant Prostate Cancer Therapeutics Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Castrate Resistant Prostate Cancer Therapeutics Total Market by Region (by Headquarter Location)
1.3.1 World Castrate Resistant Prostate Cancer Therapeutics Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Castrate Resistant Prostate Cancer Therapeutics Market Size (2018-2029)
1.3.3 China Castrate Resistant Prostate Cancer Therapeutics Market Size (2018-2029)
1.3.4 Europe Castrate Resistant Prostate Cancer Therapeutics Market Size (2018-2029)
1.3.5 Japan Castrate Resistant Prostate Cancer Therapeutics Market Size (2018-2029)
1.3.6 South Korea Castrate Resistant Prostate Cancer Therapeutics Market Size (2018-2029)
1.3.7 ASEAN Castrate Resistant Prostate Cancer Therapeutics Market Size (2018-2029)
1.3.8 India Castrate Resistant Prostate Cancer Therapeutics Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Castrate Resistant Prostate Cancer Therapeutics Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Castrate Resistant Prostate Cancer Therapeutics Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 Demand Summary
2.1 World Castrate Resistant Prostate Cancer Therapeutics Consumption Value (2018-2029)
2.2 World Castrate Resistant Prostate Cancer Therapeutics Consumption Value by Region
2.2.1 World Castrate Resistant Prostate Cancer Therapeutics Consumption Value by Region (2018-2023)
2.2.2 World Castrate Resistant Prostate Cancer Therapeutics Consumption Value Forecast by Region (2024-2029)
2.3 United States Castrate Resistant Prostate Cancer Therapeutics Consumption Value (2018-2029)
2.4 China Castrate Resistant Prostate Cancer Therapeutics Consumption Value (2018-2029)
2.5 Europe Castrate Resistant Prostate Cancer Therapeutics Consumption Value (2018-2029)
2.6 Japan Castrate Resistant Prostate Cancer Therapeutics Consumption Value (2018-2029)
2.7 South Korea Castrate Resistant Prostate Cancer Therapeutics Consumption Value (2018-2029)
2.8 ASEAN Castrate Resistant Prostate Cancer Therapeutics Consumption Value (2018-2029)
2.9 India Castrate Resistant Prostate Cancer Therapeutics Consumption Value (2018-2029)
3 World Castrate Resistant Prostate Cancer Therapeutics Companies Competitive Analysis
3.1 World Castrate Resistant Prostate Cancer Therapeutics Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Castrate Resistant Prostate Cancer Therapeutics Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Castrate Resistant Prostate Cancer Therapeutics in 2022
3.2.3 Global Concentration Ratios (CR8) for Castrate Resistant Prostate Cancer Therapeutics in 2022
3.3 Castrate Resistant Prostate Cancer Therapeutics Company Evaluation Quadrant
3.4 Castrate Resistant Prostate Cancer Therapeutics Market: Overall Company Footprint Analysis
3.4.1 Castrate Resistant Prostate Cancer Therapeutics Market: Region Footprint
3.4.2 Castrate Resistant Prostate Cancer Therapeutics Market: Company Product Type Footprint
3.4.3 Castrate Resistant Prostate Cancer Therapeutics Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 United States VS China VS Rest of the World (by Headquarter Location)
4.1 United States VS China: Castrate Resistant Prostate Cancer Therapeutics Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Castrate Resistant Prostate Cancer Therapeutics Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Castrate Resistant Prostate Cancer Therapeutics Consumption Value Comparison
4.2.1 United States VS China: Castrate Resistant Prostate Cancer Therapeutics Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Castrate Resistant Prostate Cancer Therapeutics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Castrate Resistant Prostate Cancer Therapeutics Companies and Market Share, 2018-2023
4.3.1 United States Based Castrate Resistant Prostate Cancer Therapeutics Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Castrate Resistant Prostate Cancer Therapeutics Revenue, (2018-2023)
4.4 China Based Companies Castrate Resistant Prostate Cancer Therapeutics Revenue and Market Share, 2018-2023
4.4.1 China Based Castrate Resistant Prostate Cancer Therapeutics Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Castrate Resistant Prostate Cancer Therapeutics Revenue, (2018-2023)
4.5 Rest of World Based Castrate Resistant Prostate Cancer Therapeutics Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Castrate Resistant Prostate Cancer Therapeutics Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Castrate Resistant Prostate Cancer Therapeutics Revenue, (2018-2023)
5 Market Analysis by Type
5.1 World Castrate Resistant Prostate Cancer Therapeutics Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Hormonal Therapy
5.2.2 Chemotherapy
5.2.3 Others
5.3 Market Segment by Type
5.3.1 World Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2018-2023)
5.3.2 World Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2024-2029)
5.3.3 World Castrate Resistant Prostate Cancer Therapeutics Market Size Market Share by Type (2018-2029)
6 Market Analysis by Application
6.1 World Castrate Resistant Prostate Cancer Therapeutics Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Specialty Clinic
6.2.3 Others
6.3 Market Segment by Application
6.3.1 World Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2018-2023)
6.3.2 World Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2024-2029)
6.3.3 World Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2018-2029)
7 Company Profiles
7.1 Pfizer/Astellas (Xtandi)
7.1.1 Pfizer/Astellas (Xtandi) Details
7.1.2 Pfizer/Astellas (Xtandi) Major Business
7.1.3 Pfizer/Astellas (Xtandi) Castrate Resistant Prostate Cancer Therapeutics Product and Services
7.1.4 Pfizer/Astellas (Xtandi) Castrate Resistant Prostate Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Pfizer/Astellas (Xtandi) Recent Developments/Updates
7.1.6 Pfizer/Astellas (Xtandi) Competitive Strengths & Weaknesses
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Details
7.2.2 Johnson & Johnson Major Business
7.2.3 Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Product and Services
7.2.4 Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Johnson & Johnson Recent Developments/Updates
7.2.6 Johnson & Johnson Competitive Strengths & Weaknesses
7.3 AstraZeneca/Merck (Lynparza)
7.3.1 AstraZeneca/Merck (Lynparza) Details
7.3.2 AstraZeneca/Merck (Lynparza) Major Business
7.3.3 AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Product and Services
7.3.4 AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 AstraZeneca/Merck (Lynparza) Recent Developments/Updates
7.3.6 AstraZeneca/Merck (Lynparza) Competitive Strengths & Weaknesses
7.4 Bayer
7.4.1 Bayer Details
7.4.2 Bayer Major Business
7.4.3 Bayer Castrate Resistant Prostate Cancer Therapeutics Product and Services
7.4.4 Bayer Castrate Resistant Prostate Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Bayer Recent Developments/Updates
7.4.6 Bayer Competitive Strengths & Weaknesses
7.5 Jiangsu Hengrui Pharmaceuticals
7.5.1 Jiangsu Hengrui Pharmaceuticals Details
7.5.2 Jiangsu Hengrui Pharmaceuticals Major Business
7.5.3 Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Product and Services
7.5.4 Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
7.5.6 Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
7.6 CTTQ
7.6.1 CTTQ Details
7.6.2 CTTQ Major Business
7.6.3 CTTQ Castrate Resistant Prostate Cancer Therapeutics Product and Services
7.6.4 CTTQ Castrate Resistant Prostate Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 CTTQ Recent Developments/Updates
7.6.6 CTTQ Competitive Strengths & Weaknesses
7.7 Sanofi
7.7.1 Sanofi Details
7.7.2 Sanofi Major Business
7.7.3 Sanofi Castrate Resistant Prostate Cancer Therapeutics Product and Services
7.7.4 Sanofi Castrate Resistant Prostate Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Sanofi Recent Developments/Updates
7.7.6 Sanofi Competitive Strengths & Weaknesses
7.8 Hansoh
7.8.1 Hansoh Details
7.8.2 Hansoh Major Business
7.8.3 Hansoh Castrate Resistant Prostate Cancer Therapeutics Product and Services
7.8.4 Hansoh Castrate Resistant Prostate Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Hansoh Recent Developments/Updates
7.8.6 Hansoh Competitive Strengths & Weaknesses
7.9 Clovis Oncology
7.9.1 Clovis Oncology Details
7.9.2 Clovis Oncology Major Business
7.9.3 Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Product and Services
7.9.4 Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Clovis Oncology Recent Developments/Updates
7.9.6 Clovis Oncology Competitive Strengths & Weaknesses
7.10 Zhendong Pharmaceutical
7.10.1 Zhendong Pharmaceutical Details
7.10.2 Zhendong Pharmaceutical Major Business
7.10.3 Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Product and Services
7.10.4 Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Zhendong Pharmaceutical Recent Developments/Updates
7.10.6 Zhendong Pharmaceutical Competitive Strengths & Weaknesses
8 Industry Chain Analysis
8.1 Castrate Resistant Prostate Cancer Therapeutics Industry Chain
8.2 Castrate Resistant Prostate Cancer Therapeutics Upstream Analysis
8.3 Castrate Resistant Prostate Cancer Therapeutics Midstream Analysis
8.4 Castrate Resistant Prostate Cancer Therapeutics Downstream Analysis
9 Research Findings and Conclusion
10 Appendix
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer

Tables and Figures

List of Tables
Table 1. World Castrate Resistant Prostate Cancer Therapeutics Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Castrate Resistant Prostate Cancer Therapeutics Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Castrate Resistant Prostate Cancer Therapeutics Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Castrate Resistant Prostate Cancer Therapeutics Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Castrate Resistant Prostate Cancer Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Castrate Resistant Prostate Cancer Therapeutics Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Castrate Resistant Prostate Cancer Therapeutics Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Castrate Resistant Prostate Cancer Therapeutics Players in 2022
Table 12. World Castrate Resistant Prostate Cancer Therapeutics Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Castrate Resistant Prostate Cancer Therapeutics Company Evaluation Quadrant
Table 14. Head Office of Key Castrate Resistant Prostate Cancer Therapeutics Player
Table 15. Castrate Resistant Prostate Cancer Therapeutics Market: Company Product Type Footprint
Table 16. Castrate Resistant Prostate Cancer Therapeutics Market: Company Product Application Footprint
Table 17. Castrate Resistant Prostate Cancer Therapeutics Mergers & Acquisitions Activity
Table 18. United States VS China Castrate Resistant Prostate Cancer Therapeutics Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Castrate Resistant Prostate Cancer Therapeutics Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Castrate Resistant Prostate Cancer Therapeutics Companies, Headquarters (States, Country)
Table 21. United States Based Companies Castrate Resistant Prostate Cancer Therapeutics Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share (2018-2023)
Table 23. China Based Castrate Resistant Prostate Cancer Therapeutics Companies, Headquarters (Province, Country)
Table 24. China Based Companies Castrate Resistant Prostate Cancer Therapeutics Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share (2018-2023)
Table 26. Rest of World Based Castrate Resistant Prostate Cancer Therapeutics Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Castrate Resistant Prostate Cancer Therapeutics Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share (2018-2023)
Table 29. World Castrate Resistant Prostate Cancer Therapeutics Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2018-2023) & (USD Million)
Table 31. World Castrate Resistant Prostate Cancer Therapeutics Market Size by Type (2024-2029) & (USD Million)
Table 32. World Castrate Resistant Prostate Cancer Therapeutics Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2018-2023) & (USD Million)
Table 34. World Castrate Resistant Prostate Cancer Therapeutics Market Size by Application (2024-2029) & (USD Million)
Table 35. Pfizer/Astellas (Xtandi) Basic Information, Area Served and Competitors
Table 36. Pfizer/Astellas (Xtandi) Major Business
Table 37. Pfizer/Astellas (Xtandi) Castrate Resistant Prostate Cancer Therapeutics Product and Services
Table 38. Pfizer/Astellas (Xtandi) Castrate Resistant Prostate Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Pfizer/Astellas (Xtandi) Recent Developments/Updates
Table 40. Pfizer/Astellas (Xtandi) Competitive Strengths & Weaknesses
Table 41. Johnson & Johnson Basic Information, Area Served and Competitors
Table 42. Johnson & Johnson Major Business
Table 43. Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Product and Services
Table 44. Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Johnson & Johnson Recent Developments/Updates
Table 46. Johnson & Johnson Competitive Strengths & Weaknesses
Table 47. AstraZeneca/Merck (Lynparza) Basic Information, Area Served and Competitors
Table 48. AstraZeneca/Merck (Lynparza) Major Business
Table 49. AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Product and Services
Table 50. AstraZeneca/Merck (Lynparza) Castrate Resistant Prostate Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. AstraZeneca/Merck (Lynparza) Recent Developments/Updates
Table 52. AstraZeneca/Merck (Lynparza) Competitive Strengths & Weaknesses
Table 53. Bayer Basic Information, Area Served and Competitors
Table 54. Bayer Major Business
Table 55. Bayer Castrate Resistant Prostate Cancer Therapeutics Product and Services
Table 56. Bayer Castrate Resistant Prostate Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Bayer Recent Developments/Updates
Table 58. Bayer Competitive Strengths & Weaknesses
Table 59. Jiangsu Hengrui Pharmaceuticals Basic Information, Area Served and Competitors
Table 60. Jiangsu Hengrui Pharmaceuticals Major Business
Table 61. Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Product and Services
Table 62. Jiangsu Hengrui Pharmaceuticals Castrate Resistant Prostate Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 64. Jiangsu Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
Table 65. CTTQ Basic Information, Area Served and Competitors
Table 66. CTTQ Major Business
Table 67. CTTQ Castrate Resistant Prostate Cancer Therapeutics Product and Services
Table 68. CTTQ Castrate Resistant Prostate Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. CTTQ Recent Developments/Updates
Table 70. CTTQ Competitive Strengths & Weaknesses
Table 71. Sanofi Basic Information, Area Served and Competitors
Table 72. Sanofi Major Business
Table 73. Sanofi Castrate Resistant Prostate Cancer Therapeutics Product and Services
Table 74. Sanofi Castrate Resistant Prostate Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Sanofi Recent Developments/Updates
Table 76. Sanofi Competitive Strengths & Weaknesses
Table 77. Hansoh Basic Information, Area Served and Competitors
Table 78. Hansoh Major Business
Table 79. Hansoh Castrate Resistant Prostate Cancer Therapeutics Product and Services
Table 80. Hansoh Castrate Resistant Prostate Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Hansoh Recent Developments/Updates
Table 82. Hansoh Competitive Strengths & Weaknesses
Table 83. Clovis Oncology Basic Information, Area Served and Competitors
Table 84. Clovis Oncology Major Business
Table 85. Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Product and Services
Table 86. Clovis Oncology Castrate Resistant Prostate Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Clovis Oncology Recent Developments/Updates
Table 88. Zhendong Pharmaceutical Basic Information, Area Served and Competitors
Table 89. Zhendong Pharmaceutical Major Business
Table 90. Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Product and Services
Table 91. Zhendong Pharmaceutical Castrate Resistant Prostate Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 92. Global Key Players of Castrate Resistant Prostate Cancer Therapeutics Upstream (Raw Materials)
Table 93. Castrate Resistant Prostate Cancer Therapeutics Typical Customers
List of Figure
Figure 1. Castrate Resistant Prostate Cancer Therapeutics Picture
Figure 2. World Castrate Resistant Prostate Cancer Therapeutics Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Castrate Resistant Prostate Cancer Therapeutics Total Market Size (2018-2029) & (USD Million)
Figure 4. World Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Castrate Resistant Prostate Cancer Therapeutics Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Castrate Resistant Prostate Cancer Therapeutics Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Castrate Resistant Prostate Cancer Therapeutics Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Castrate Resistant Prostate Cancer Therapeutics Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Castrate Resistant Prostate Cancer Therapeutics Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Castrate Resistant Prostate Cancer Therapeutics Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Castrate Resistant Prostate Cancer Therapeutics Revenue (2018-2029) & (USD Million)
Figure 13. Castrate Resistant Prostate Cancer Therapeutics Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Castrate Resistant Prostate Cancer Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 16. World Castrate Resistant Prostate Cancer Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Castrate Resistant Prostate Cancer Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 18. China Castrate Resistant Prostate Cancer Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Castrate Resistant Prostate Cancer Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Castrate Resistant Prostate Cancer Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Castrate Resistant Prostate Cancer Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Castrate Resistant Prostate Cancer Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 23. India Castrate Resistant Prostate Cancer Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Castrate Resistant Prostate Cancer Therapeutics by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Castrate Resistant Prostate Cancer Therapeutics Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Castrate Resistant Prostate Cancer Therapeutics Markets in 2022
Figure 27. United States VS China: Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Castrate Resistant Prostate Cancer Therapeutics Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Castrate Resistant Prostate Cancer Therapeutics Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Castrate Resistant Prostate Cancer Therapeutics Market Size Market Share by Type in 2022
Figure 31. Hormonal Therapy
Figure 32. Chemotherapy
Figure 33. Others
Figure 34. World Castrate Resistant Prostate Cancer Therapeutics Market Size Market Share by Type (2018-2029)
Figure 35. World Castrate Resistant Prostate Cancer Therapeutics Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 36. World Castrate Resistant Prostate Cancer Therapeutics Market Size Market Share by Application in 2022
Figure 37. Hospital
Figure 38. Specialty Clinic
Figure 39. Others
Figure 40. Castrate Resistant Prostate Cancer Therapeutics Industrial Chain
Figure 41. Methodology
Figure 42. Research Process and Data Source




Companies Mentioned
Pfizer/Astellas (Xtandi)
Johnson & Johnson
AstraZeneca/Merck (Lynparza)
Bayer
Jiangsu Hengrui Pharmaceuticals
CTTQ
Sanofi
Hansoh
Clovis Oncology
Zhendong Pharmaceutical

Reason to Buy

  • Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The segment that is expected to dominate the Pharma & Healthcare Market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets